Xiretsa Inc is second venture to receive INCATE Stage II Funding.
Xiretsa, Inc is the second selected venture to receive INCATEs Stage II Funding. The €250k grant will allow the team to accelerate hit-to-lead activities and secure space at California NanoSystems Institute Technology Incubator on the campus of University of California, Santa Barbara.
Since being selected for Stage I in March 2023, the Xiretsa team has refined their development strategy and was accepted into the Chemistry Center for Combating Antibiotic Resistant Bacteria (CC4CARB) program. Together with the Walter Reed Army Institute of Research, the team has initiated a new effort focused on K. pneumoniae lung and wound infections with promising preliminary results.
The INCATE Selection Committee was convinced not only by the dynamic team, but also by the fact that their core technology represents a new class of molecules targeting a unique mechanism of action which shows a low likelihood of resistance development.
